Navigation Links
Neurocrine Biosciences Reports Second Quarter 2009 Results
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended June 30, 2009. For the second quarter of 2009, the Company reported a net loss of $15.3 million, or $0.39 per share, compared with a net loss of $21.0 million, or $0.55 per share, for the same period in 2008. For the six months ended June 30, 2009, the Company reported a net loss of $34.9 million, or $0.90 per share, as compared to $42.0 million, or $1.10 per share, for the same period last year.

Revenues for the second quarter of 2009 and 2008 were $0.7 million. Revenues for the six months ended June 30, 2009 were $1.5 million, compared with $2.5 million for the same period in 2008. The decrease in revenues is primarily due to milestones recognized in 2008 under our collaboration agreement with GlaxoSmithKline (GSK) related to the clinical advancements of our CRF program. During both six month periods ended June 30, 2009 and 2008, we recognized $1.5 million in revenue under our collaboration agreement for indiplon with Dainippon Sumitomo Pharma Co. Ltd. (DSP) from amortization of up-front licensing fees.

Research and development expenses decreased to $10.8 million during the second quarter of 2009 compared with $16.2 million for the same period in 2008. For the six months ended June 30, 2009, research and development expenses were $21.7 million, compared to $30.4 million for the same period last year. The decrease in research and development expenses is primarily due to expense management efforts and decreasing external clinical development expenses related to the elagolix program.

General and administrative expenses were $4.8 million for the second quarter of 2009 and $4.7 million during the same period last year. For t
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
3. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
4. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
5. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
8. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
9. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
10. Neurocrine Announces Work Force Restructuring
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2, 2015 Amici Procurement Migrates ... company Amici Procurement has chosen Microsoft Cloud Solution Provider ... to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... medium-sized companies in the bio-tech sector with a unique ... purchasing cycle to help them obtain best value. Its ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, ... over 20,000 brain scans and is believed to be the largest brain imaging study ...
(Date:7/1/2015)... ... 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised for ... diagnostics industry. BCC Research reveals in its new report that the market drivers of ... a growing need for better diagnostics as part of a molecular diagnostics trend. , ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... Pilot Therapeutics Inc., a,Nutritional Therapeutics Innovation Company, today ... Keith Wakeman as President. "Pilot has always ... food and dietary supplement areas with over 60 ... the potential to rapidly move our,world class technologies ...
... be Featured on Oct 25, 2007 -, ... VIAP ) a biotechnology company focused on the ... announced today that,Windhover Information has chosen the company,s ... most interesting cardiovascular projects available for,partnering. VIA will ...
... 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced preliminary ... 30, 2007 and updated its financial,outlook for ... in conjunction with the,release of Boston Scientific ...
Cached Biology Technology:Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses 2VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference 2VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference 3VIA Pharmaceuticals' Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Information's Therapeutic Area Partnerships Conference 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 3Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 5Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 6Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 7Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 8Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 9Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 10Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 11
(Date:6/17/2015)... GERMANTOWN, Maryland , June 17, 2015 ...   Produktlinie mit DNA-Tests verbessert den Analyseprozess und ... QGEN ; Frankfurt Prime Standard: QIA) hat heute in ... Produktlinie Investigator ® für ... Die neuen Kits zur Erstellung genetischer Fingerabdrücke bieten eine ...
(Date:6/17/2015)... Fla. , June 17, 2015  Crossmatch™, ... today announced that its U.are.U ® 4500 ... Togo,s Eateries, Inc., a ... sandwich chain, to increase security, improve accountability and ... readers enable instant, non-repudiable identity confirmation for employee ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
...  Aware, Inc. (NASDAQ: AWRE ), a leading ... today reported financial results for its third quarter ended ... service assurance hardware business have been reported as discontinued ... of that business during the third quarter. Accordingly, results ...
... the chief of naval research, told a packed house at ... conference this week that he intends to bring officials from ... quarterly basis, starting in 2013, to accelerate S&T efforts for ... which is phenomenal and very valuableand probably not enough," said ...
... COLUMBUS, Ohio More than 80 percent of pigs that tested ... and 2011 showed no signs of illness, according to a new ... at 53 fair events over those three summers and found at ... of fairs tested. The influenza strains identified in pigs ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6In an uncertain world, Navy needs science and technology collaboration, chief says 2Pigs look healthy but test positive for flu at fairs; transmission seen between pigs and humans 2Pigs look healthy but test positive for flu at fairs; transmission seen between pigs and humans 3Pigs look healthy but test positive for flu at fairs; transmission seen between pigs and humans 4
Mouse monoclonal [164-12-2] to Ampicillin ( Abpromise for all tested applications)....
... The product contains 5 ml Dynabeads Epoxy ... glycidyl ether (epoxy) reactive groups. Ideal for ... are absorbed hydrophobically on initial coupling with ... 2 and sulphydryll groups (SH)) occurring ...
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
...
Biology Products: